Abstract:
:There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at the standard dosage (75 mg/m2 ). Median time from diagnosis to AP/BP evolution was 92.3 months (IR 29.9-180.1). All patients were evaluable for hematologic response: two patients (5.2%) died early after AZA initiation, 13 patients (33.3%) had a progressive or stable disease, nine (23.1%) had a hematologic improvement (HI), seven (17.9%) achieved a partial response (PR), and eight (20.5%) a complete response (CR). Overall, 24 patients achieved a clinical hematologic response (HI + PR + CR), with an overall response rate of 61.5%. Median overall survival (OS) from AZA start of the whole cohort was 13.5 months (95% CI, 8.2-18.7). There was no difference in median OS among patients with HI, PR, or CR (P = .908). These three subgroups as "responders" having been considered, a significantly better OS was observed in responder compared with nonresponder patients, with a median OS of 17.6 months (95% CI, 10.1-25.0) versus 4.1 months (95% CI, 0.4-10.0) (P = .001) Only female gender was significant for both achievement of response (.010) and OS duration (P = .002). In conclusion, AZA is useful for the management of MPN-AP/BP, with an overall response rate (HI + PR + CR) of 61.5% and a longer OS in responders.
journal_name
Hematol Oncoljournal_title
Hematological oncologyauthors
Andriani A,Elli E,Trapè G,Villivà N,Fianchi L,Di Veroli A,Niscola P,Centra A,Anaclerico B,Montanaro G,Martini V,Aroldi A,Carmosino I,Voso MT,Breccia M,Montanaro M,Foà R,Latagliata Rdoi
10.1002/hon.2635subject
Has Abstractpub_date
2019-08-01 00:00:00pages
291-295issue
3eissn
0278-0232issn
1099-1069journal_volume
37pub_type
杂志文章,多中心研究abstract::Bone marrow interstitial fluid (BMIF) has not been well characterized. BMIF was isolated from 60 patients including plasma cell dyscrasias (PCD, n = 33), other primary hematologic disorders (OHD, n = 15), and patients with secondary or nonhemtologic disorders (NHD, n = 12) and analyzed for an array of chemical constit...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2493
更新日期:2018-04-01 00:00:00
abstract::Cytotoxic and DNA synthesis inhibitory effects of several iron chelators with different physicochemical properties have been tested in four myeloid leukaemic cell lines (U937, K562, ML2 and HL60). The small lipophilic chelators 8-hydroxyquinoline, tropolone and omadine at 2 X 10(-5) M, caused substantial inhibition of...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900040303
更新日期:1986-07-01 00:00:00
abstract::Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) have a great value in clinical practice of gastrointestinal lymphoma (GIL). Auxiliary methods such as flow cytometry (FCM) and gene rearrangement provide additional information for the diagnosis. Current study aims to explore the diagnostic va...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2298
更新日期:2017-09-01 00:00:00
abstract::Pediatric-type follicular lymphoma (PTFL), pediatric nodal marginal zone lymphoma (pnMZL), and large B-cell lymphoma (LBCL) with IRF4 rearrangement have been introduced into the current World Health Organization (WHO) classification. They account for 5% to 10% of mature B-cell lymphomas in children and adolescents. Bo...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2585
更新日期:2019-06-01 00:00:00
abstract::Delayed platelet recovery (DPR) despite prompt neutrophil engraftment is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT). However, few studies have evaluated the risk factors and long-term outcome. Therefore, we retrospectively analysed 219 adult patients who underwent their first a...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2427
更新日期:2018-02-01 00:00:00
abstract::The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacit...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2646
更新日期:2019-10-01 00:00:00
abstract::Mantle cell lymphoma (MCL) is a lymphoproliferative disorder characterized by the t(11;14)(q13;q32) CCND1/IGH translocation. This lymphoma is however extremely heterogeneous in terms of molecular alterations. Moreover, the course of the disease can vary greatly between indolent forms with slow progression and aggressi...
journal_title:Hematological oncology
pub_type: 杂志文章,随机对照试验
doi:10.1002/hon.2750
更新日期:2020-10-01 00:00:00
abstract::Post-transplant lymphoproliferative disorders (PTLD) are a major problem in transplant medicine. So far, the insights into pathogenesis and potentially druggable pathways in PTLD remain scarce. We investigated a cohort of PTLD patients, consisting of both polymorphic (n = 3) and monomorphic (n = 19) B-cell lymphoproli...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2280
更新日期:2017-06-01 00:00:00
abstract::The relationship between myeloblast-like cells and cluster-forming cells detected by growth in agar has been studied in 22 untreated patients with acute non-lymphocytic leukemia by means of comparing data for 3H-TdR labelling of myeloblast-like cells and 3H-TdR suiciding of cluster-forming cells. The fraction of myelo...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900020210
更新日期:1984-04-01 00:00:00
abstract::One hundred and twenty-five cases of acute myeloid leukemia (AML) were reviewed for the presence of Auer rods by two peroxidase methods. The percentage of Auer rods recognized by Wright-Giemsa (WG) staining was 20.8% but three times higher by peroxidase staining techniques using either benzidine base as a substrate (P...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900050306
更新日期:1987-07-01 00:00:00
abstract::Reactivation of remote hepatitis B infection (RHBI) is an important cause of morbidity in hematopoietic cell transplant (HCT) patients. We analyzed the prevalence of RHBI in 205 patients who underwent HCT in our centre, serological events related to hepatitis B virus (HBV) reactivation and role of lamivudine prophylax...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2195
更新日期:2016-09-01 00:00:00
abstract::Eighty-eight patients with low grade non-Hodgkin's lymphoma were followed for a median period of 63 months. Sixty-eight per cent of the group were centrocytic/centroblastic B cell lymphomas by the updated Kiel classification. Fifty-one (58 per cent) of the patients were stage IV by the Ann Arbor classification. In 18 ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900120104
更新日期:1994-01-01 00:00:00
abstract::The cause of myelosuppression in hairy cell leukemia (HCL) has been ascribed to a reduction of the circulating progenitor cell (CPC) compartment and to suppression of hematopoiesis by TNF-alpha. The present study was performed to evaluate the inhibitory effect of hairy cells (HCs) and a possible lack of hematopoietic ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900110207
更新日期:1993-03-01 00:00:00
abstract::We have treated 11 patients with relapsed or resistant lymphoma with a combination of Etoposide, Prednisolone, Ifosfamide and Carboplatin (EPIC), obtaining complete responses in two patients and partial responses in four patients for an overall response rate of 54 per cent. The treatment was well tolerated with no tox...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900120304
更新日期:1994-05-01 00:00:00
abstract::For finding better method of acute myeloid leukaemia (AML) induction, we designed a prospective clinical trial to find a more effective regimen with least toxicity for induction therapy of AML. Hence, we examined different accepted doses of daunorubicin and their outcomes. Total of 114 patients were included in the st...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/hon.2236
更新日期:2017-03-01 00:00:00
abstract::Previous studies have shown that the incidence of non-Hodgkin's lymphoma (NHL) has increased in many parts of the world in recent decades. Using data obtained from the Canadian Cancer Registry, the present study examined time trends in NHL incidence in Canada between 1970 and 1996 and the effects of age, period of dia...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.703
更新日期:2003-06-01 00:00:00
abstract::The aim of this study was to explore the expression of retinoblastoma protein and EBV status in a cohort of cases of Hodgkin's disease from South Africa. Seventy one cases of Hodgkin's disease were accessed over a 6-year period and were classified according to the Rye Classification. Relevant sections were stained wit...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/(sici)1099-1069(199711)15:4<191::aid-hon61
更新日期:1997-11-01 00:00:00
abstract::Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cells (PBM) from patien...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900080205
更新日期:1990-03-01 00:00:00
abstract::Advanced-stage mycosis fungoides and Sezary syndrome (MF/SS) have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT), particularly using a reduced-intensity conditioning (RIC) regimen, is a promising treatment for advanced-stage MF/SS. We performed RIC-HSCT in nine patients with advanced MF/SS...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2162
更新日期:2016-03-01 00:00:00
abstract::In the last four years we established five long term cultures from tumor material of Hodgkin's disease. The in vitro cells have malignant characteristics and represent the in vivo H- and SR-cells. Common immunological, functional and morphological assays did not characterize the in vitro cells to be a known cell type ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900010204
更新日期:1983-04-01 00:00:00
abstract::Fourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and adriamycin administered on days 1-8. Recombinant human g...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900090608
更新日期:1991-11-01 00:00:00
abstract::Fertility preservation embraces different techniques developed to improve young women chances of becoming mothers after healing. Among them, in vitro maturation (IVM) procedure is based on oocyte retrieval without any gonadotropin treatment, feasible under locoregional or local anesthesia, with very low operative comp...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2724
更新日期:2020-10-01 00:00:00
abstract::We have collected, by an active retrospective survey, all the cases of hematologic malignancies (HM) newly diagnosed during the time period 1974-1993 in the resident population of Sardinia. Diagnosis was deemed valid, after consultation of clinical records, in more than 90% of the 7264 collected cases. The number of n...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.733
更新日期:2004-09-01 00:00:00
abstract::Childhood leukemia is the commonest form of childhood cancer and represents clonal proliferation of transformed hemopoietic cells as a result of genetic changes. Molecular characterization of these changes, in particular chromosomal translocations, has yielded a wealth of information on the mechanisms of leukemogenesi...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/(sici)1099-1069(199909)17:3<91::aid-hon643
更新日期:1999-09-01 00:00:00
abstract::In 2009, the four laboratories of the Fondazione Italiana Linfomi (FIL) minimal residual disease (MRD) Network started a collaborative effort to harmonize and standardize their methodologies at the national level, performing quality control (QC) rounds for follicular lymphoma (FL) and mantle cell lymphoma (MCL) MRD as...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2652
更新日期:2019-10-01 00:00:00
abstract::Several studies have shown that adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or reducing the interval between chemotherapy cycles from 3 weeks to 2 weeks improves survival in patients with diffuse large B-cell lymphoma (DLBCL). These studies prompted our group (GOTEL) to evaluate...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.829
更新日期:2008-03-01 00:00:00
abstract::Langerhans cell histiocytosis (LCH) is rare in adults, and only a subset of these patients suffers from central nervous system (CNS) involvement. Hence, evidence-based treatment recommendations are lacking. A case of a 20-year-old student with multisystem LCH and extensive CNS involvement is described, who showed a du...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.1005
更新日期:2012-06-01 00:00:00
abstract::Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overa...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/hon.2522
更新日期:2018-12-01 00:00:00
abstract::Previous meta-analyses suggested that acute myeloid leukaemia induction regimens containing idarubicin (IDA) or high-dose daunorubicin (HDD) induce higher rates of complete remission (CR) than conventional-dose daunorubicin (CDD), with a possible benefit in overall survival. However, robust comparisons between these r...
journal_title:Hematological oncology
pub_type: 杂志文章,meta分析
doi:10.1002/hon.2173
更新日期:2015-12-01 00:00:00
abstract::We assessed the efficacy of an etoposide, ifosfamide and methotrexate combination therapy (VIM) in 24 patients failing the LNH 84 protocol. Eight of these patients were refractory to the LNH 84 induction regimen, 10 were partial responders and the six remaining attained complete response after LNH 84 induction but rel...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1002/hon.2900090411
更新日期:1991-07-01 00:00:00